Praluent (Alirocumab): First PCSK9 Inhibitor Approved by the FDA for Hypercholesterolemia

Documenti analoghi

• Alirocumab (Praluent): First in the New Class of PCSK9 Inhibitors
  di: Manniello, Marina, et al.
  Pubblicazione: (2016)
• Repatha (Evolocumab): Second PCSK9 Inhibitor Approved by the FDA for Patients with Familial Hypercholesterolemia
  di: Fala, Loretta
  Pubblicazione: (2016)
• Revlimid (Lenalidomide) Now FDA Approved as First-Line Therapy for Patients with Multiple Myeloma
  di: Raedler, Lisa A.
  Pubblicazione: (2016)
• Jakafi (Ruxolitinib): First FDA-Approved Medication for the Treatment of Patients with Polycythemia Vera
  di: Raedler, Lisa A.
  Pubblicazione: (2015)
• Early effects of PCSK9 inhibitors: evolocumab versus alirocumab
  di: Su-Hyun Bae, et al.
  Pubblicazione: (2025-03-01)